This study innovatively integrates ovarian tumor markers (CA125/HE4) with systemic inflammatory indices (NLR, PLR, MLR, SII) to enhance early OC detection accuracy and ultimately improve patient outcomes. The gene discussed is MUC16; the disease is ovarian neoplasm.